Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study
Open Access
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 29 (9) , 105034
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Pfizer Japan
- Bristol-Myers Squibb
- Bayer
- Daiichi Sankyo Company
This publication has 25 references indexed in Scilit:
- Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF RegistryPLOS ONE, 2015
- Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Guidelines, Update 2014International Journal of Stroke, 2014
- Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic AttackStroke, 2014
- Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013)Circulation Journal, 2014
- Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialThe Lancet Neurology, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial FibrillationChest, 2010
- Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examinationInternational Journal of Cardiology, 2009
- Mortality Risk Attributable to Atrial Fibrillation in Middle-Aged and Elderly People in the Japanese General PopulationCirculation Journal, 2007
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991